Fisher Asset Management LLC Makes New $757,000 Investment in Tyra Biosciences, Inc. $TYRA

Fisher Asset Management LLC acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 28,800 shares of the company’s stock, valued at approximately $757,000.

A number of other hedge funds have also recently modified their holdings of TYRA. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after buying an additional 534 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after acquiring an additional 1,668 shares during the period. Federated Hermes Inc. boosted its stake in Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after acquiring an additional 1,841 shares in the last quarter. Chung Wu Investment Group LLC bought a new stake in Tyra Biosciences during the fourth quarter worth about $53,000. Finally, Oppenheimer & Co. Inc. grew its holdings in Tyra Biosciences by 3.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 84,726 shares of the company’s stock worth $2,227,000 after purchasing an additional 2,488 shares during the period. Institutional investors own 84.14% of the company’s stock.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Gilla Kaplan sold 14,295 shares of the company’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total transaction of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 12.50% of the stock is owned by corporate insiders.

Tyra Biosciences Stock Up 2.2%

NASDAQ:TYRA opened at $33.41 on Friday. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -15.33 and a beta of 0.79. The company’s 50 day moving average price is $35.65 and its 200-day moving average price is $30.27. Tyra Biosciences, Inc. has a 52 week low of $8.88 and a 52 week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). As a group, sell-side analysts anticipate that Tyra Biosciences, Inc. will post -2.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Tyra Biosciences in a report on Tuesday, February 24th. They set an “overweight” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Tyra Biosciences in a research report on Thursday, May 14th. Piper Sandler lifted their price objective on Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a research note on Friday, March 20th. Jefferies Financial Group increased their target price on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, February 3rd. Finally, William Blair started coverage on Tyra Biosciences in a report on Tuesday, February 10th. They set an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and a consensus target price of $46.50.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.